• In late June 2026, Lantheus Holdings reported that the FDA issued a Complete Response Letter for its LNTH-2501 PET imaging kit for somatostatin receptor‑positive neuroendocrine tumors, citing unresolved third‑party manufacturing facility issues rather than concerns about the product’s safety, efficacy, or supporting data.
• Separately, the company was added to both the Russell 2000 Defensive Index and the Russell 2000 Growth‑Defensive Index, highlighting its growing profile within defensive healthcare equities even as regulatory timing for LNTH-2501 remains dependent on resolving external manufacturing conditions.
• We’ll now examine how the FDA’s facility‑related delay for LNTH-2501 may influence Lantheus’s radiodiagnostic growth narrative and risk profile.

Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

Lantheus Holdings Investment Narrative Recap

To own Lantheus today, you need to believe its radiopharmaceutical portfolio can offset pressures in PSMA PET imaging and heavy reliance on PYLARIFY. The LNTH-2501 Complete Response Letter looks more like a timing setback than a product readout issue, but it adds regulatory and execution risk to near term radiodiagnostic growth. In the short term, the key catalyst remains the rollout of the new PYLARIFY formulation, while the biggest risk is continued pricing and reimbursement pressure in prostate cancer imaging.

The most relevant recent announcement alongside the LNTH-2501 delay is Lantheus’s addition to the Russell 2000 Defensive and Russell 2000 Growth Defensive Indexes. Index inclusion can increase visibility among healthcare and defensive equity investors at the same time the company faces facility related regulatory delays. That contrast reinforces the importance of watching how quickly LNTH-2501’s manufacturing issues are resolved relative to other pipeline catalysts coming in 2026.

Yet beneath the defensive label, investors should be aware of how concentrated product exposure and facility related delays could...

Lantheus Holdings' narrative projects $1.9 billion revenue and $431.2 million earnings by 2029. This requires 7.4% yearly revenue growth and about a $152 million earnings increase from $279.0 million today.

Uncover how Lantheus Holdings' forecasts yield a $104.08 fair value, a 5% downside to its current price.

Exploring Other Perspectives

Some of the lowest analysts were already cautious, assuming only 3.7% annual revenue growth to about US$1.7 billion by 2029 and modest margin gains, so this kind of facility driven delay may reinforce their concern that slow adoption and regulatory holdups, especially around products like LNTH 2501, could leave earnings closer to US$286.6 million than the higher estimates others expect.

Explore 6 other fair value estimates on Lantheus Holdings - why the stock might be worth as much as 90% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Lantheus Holdings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Lantheus Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Lantheus Holdings' overall financial health at a glance.

Seeking Other Investments?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 31 companies in the world exploring or producing it. Find the list for free.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.